Italy · Delayed Price · Currency is EUR GVS S.p.A. Earnings Call Transcripts
Fiscal Year 2025
-
Sales grew 2% year-over-year excluding FX, with adjusted EBITDA up 3% and margin at 25.2%. Guidance for 2026 is low single-digit growth, 20-50 bps EBITDA margin improvement, and a leverage ratio of 1.8, amid ongoing FX and raw material risks.
-
Healthcare and life science and safety divisions delivered strong growth, while mobility faced headwinds. Adjusted EBITDA margin improved, and guidance for 2025 points to further margin expansion and cash generation, with new product launches and operational efficiencies expected to drive future growth.
-
Record EBITDA and margin expansion achieved, driven by core MedTech and Safety growth, price increases, and operational improvements. Guidance for mid-high single-digit revenue growth and further margin gains is confirmed, with strong cash generation and dividend planned by year-end.
-
Q1 sales grew 3.2% to EUR 107 million, with EBITDA up 6.1% and net income up 21.6%. Exceptional events delayed some sales to Q2, but guidance for mid-high single-digit growth and improved margins is confirmed. Leverage is targeted below 2 by year-end.
Fiscal Year 2024
-
Revenue rose 1.5% to €430M, with EBITDA up 10% and net income up 52%. 2025 guidance targets mid-high single digit growth, margin expansion, and leverage below 2x, with Transfusion Medicine integration and new products as key drivers.
-
Revenue grew nearly 4% year-over-year with EBITDA margin up 220 bps to 24.3%, driven by strong Healthcare & Safety segments. Leverage ratio fell to 2.3, and 2024 guidance for growth and margin improvement is confirmed despite ongoing challenges in Energy & Mobility.
-
Revenue grew 1.6% year-over-year to €250 million, with adjusted EBITDA up 11% and margin at 24.2%. Health and Safety led growth, while Energy and Mobility faced delays but expects recovery. Guidance for sales and margin was raised, with strong cash generation and a stable outlook.